Drug intelligence / Profile preview

Nopan

Development stage: Phase 3
Lead developer: Grünenthal
Modality: Small Molecules
Administration: Sublingual

Overview

Nopan is a mixed opioid agonist-antagonist that has demonstrated antidepressant effects with a rapid onset of action in anecdotal evidence and several clinical studies. It is currently being investigated as a novel and quick-acting treatment for acute suicidality.

Brand names: Nopan
Other names: ultra-low-dose buprenorphinebuprenorphine hydrochloride

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Nopan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nopan.

Explore the full profile